Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Khartis Therapeutics has raised $50 million in a Series B funding round led by Forge Life Science Partners to advance its oral small molecule immunology pipeline.
PRIVATEAug 13, 2026•about 3 hours ago
Amount Raised
$50 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeuticsInvestors
Nextech InvestLilly Asia VenturesForesite CapitalAlexandria Venture InvestmentsLongwood FundForge Life Science Partners
Description
Khartis Therapeutics, a biotechnology company, has emerged from stealth mode with a successful Series B financing round. The company raised $50 million to advance its development of oral small molecule medicines targeting immunological and chronic diseases. This funding round saw participation from notable investors such as Longwood Fund and Alexandria Venture Investments, along with existing supporters. The new capital will help propel the company's innovative pipeline forward.
Don't miss Khartis Therapeutics's next move
Get an email the moment Khartis Therapeutics raises, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Funding Insights
Based on industry dataTimeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech